The Federal Trade Commission (FTC) settled a lawsuit that BIO’s amicus brief warned would “chill investment, with predictable and unwelcome results for innovation and drug development.”
ICYMI: The FTC sued to block Amgen from acquiring Horizon Therapeutics; both companies are BIO members. Last week, Amgen announced the settlement, saying it “will have no impact on Amgen’s business.”
BIO filed an amicus brief on Aug. 24 arguing FTC’s unusual overreach created market uncertainty, casting doubt on the biotech dealmaking essential to developing lifesaving innovations.
The importance of M&A: “Mergers and acquisitions help define much of the biopharmaceutical innovation ecosystem,” said BIO. FTC has traditionally recognized that mergers increase competition, and changing this approach would harm investment, the brief said.
More Health News:
Rockland/Westchester Journal News: Pfizer’s women leaders talk representation, mentoring, and vaccine hesitancy
“Pfizer’s research team at their Rockland campus now has all-female leadership — five top scientists at the world-renown research site are women. As such, they are in charge of innovating new approaches to vaccines amid growing vaccine hesitation, emerging infectious diseases and recirculating viruses once considered tamed.”
